|
The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: ---------- ECR Minerals PLC - Australia-focused gold exploration and development company - Reports drilling results at its Blue Mountain project in Queensland, expanding the alluvial gold footprint and strengthening the case for near-term, low-cost production. The company says visible coarse gold is identified in multiple samples from the newly defined Upper Kariboe Creek flat, with mineralisation now mapped over around 250 metres of strike. Nineteen intersections exceed the 0.15 g/b.c.m cut-off grade, including grades up to 6.52 g/b.c.m. Wash-plant trials at Lower Patterson continue to show practical mining grades averaging 0.35 g/b.c.m, and ECR notes several potential start-up zones across the project. ---------- Blencowe Resources PLC - London-based mining company - Reports ‘exceptional’ initial results from the first deep hole drilled at the newly identified Iyan deposit within its Orom-Cross graphite project in Uganda, confirming what it calls a major new mineralised zone. The hole intercepts near-continuous high-grade graphite from 4 metres below surface to roughly 100 metres, ending while still in mineralisation. Key intervals include 18.85 metres at 7.01% TGC, 29.47 metres at 5.34% TGC, and 10.88 metres at 5.10% TGC. ---------- Roquefort Therapeutics PLC - London-based biotech firm developing medicines in immunology and oncology sectors - Reports progress on its AO-252 development and confirms amended terms on its licensing deal with Coiled Therapeutics Inc and A2A Pharma Inc. Coiled USA receives approval to widen its phase I trial protocol to all solid tumours and, following encouraging safety signals, prioritises metastatic castration-resistant prostate cancer as the lead indication. The first patient in this cohort is already enrolled and dosed at the 4b dose level, where the strongest clinical benefit has been seen so far. Roquefort says the strategic shift is supported by strong pre-clinical data, including complete or partial responses in VCaP xenograft models, 60% tumour growth inhibition in AR-independent models, and 90% TGI in 22Rv1 AR-resistant models. Efficacy appears independent of androgen signalling, suggesting potential utility in resistant disease. Commercial interest in oral targeted cancer therapies has been reinforced by Johnson & Johnson’s $3.05 billion acquisition of Halda Therapeutics last month, the company notes. ---------- Haydale Graphene Industries PLC - Carmarthenshire, Wales-based developer of materials using graphene and other nanomaterials - Announces placing, subscription and retail offer to raise up to £6.4 million. Expects the placing and subscription to raise up to £5.9 million, with the retail offer to raise up to £500,000. Issue price for the fundraising is 0.5p per share. Also, Haydale has conditionally agreed to acquire Intelligent Resource Management Ltd, an end-to-end energy efficiency solutions provider which trades as SaveMoneyCutCarbon or SMCC, for all-share consideration of up to £17.1 million, of which £11.2 million will be paid on completion. Finally, the board intends to change the firm’s name to Haydale PLC, ‘reflecting the evolution of the group into a broader clean-technology platform’. ---------- Firering Strategic Minerals PLC - Firering Strategic Minerals PLC - Zambia and Ivory Coast-focused mining company - Says Ricca Resources has now approved all resolutions at its EGM, allowing the previously agreed $1 million settlement to complete. Firering expects to receive the full amount as payment for all debts and claims owed by Ricca. The company also reiterates that Ricca is expected to distribute net proceeds to shareholders following the sale of a subsidiary for A$4.4 million, around £2.2 million, subject to an adjustment of up to A$332,000 payable to Skylark Minerals. Firering holds a 10.6% stake in Ricca and anticipates benefiting from the planned distribution once the sale process concludes. ---------- Neo Energy Metals PLC - uranium and gold projects in South Africa - Provides a detailed update on its planned acquisition of the Beisa uranium and gold mine in South Africa, saying it expects to secure all remaining regulatory approvals in both South Africa and the UK in the first quarter of 2026. The company says the conditional acquisition from Sibanye-Stillwater remains on track, with approval applications under section 11 and section 102 of South Africa’s Mineral & Petroleum Resources Development Act still progressing. Neo has already received South African Reserve Bank approval for a R 1.2 billion shareholder loan facility to support working capital needs, and in the UK has appointed a rule 3 adviser for the rule 9 waiver required as Sibanye is set to become its largest shareholder with up to a 40% stake. ---------- Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
